Scarica l'app Stockscreener
14.51
0.28%
-0.010
Precedente Chiudi:
$14.52
Aprire:
$14.55
Volume 24 ore:
84,543
Relative Volume:
0.08
Capitalizzazione di mercato:
$883.66M
Reddito:
$10.00M
Utile/perdita netta:
$-113.63M
Rapporto P/E:
-7.9143
EPS:
-1.8334
Flusso di cassa netto:
$-83.28M
1 W Prestazione:
+4.85%
1M Prestazione:
-3.53%
6M Prestazione:
-58.26%
1 anno Prestazione:
-42.59%
Intervallo 1D:
$14.43
$14.67
Intervallo di 1 settimana:
$13.98
$14.87
Portata 52W:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.49 | 885.49M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
436.11 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.73 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.68 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.75 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.51 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Downgrade | Barclays | Overweight → Underweight |
| 2026-04-15 | Downgrade | UBS | Buy → Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How (JANX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value - TipRanks
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12 - MSN
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus
Janux Therapeutics VP Maria Dobek sells $28,878 in stock By Investing.com - Investing.com Australia
Janux Therapeutics VP Maria Dobek sells $28,878 in stock - Investing.com India
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 - Stock Titan
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts - simplywall.st
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics - Stock Titan
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target - TipRanks
Lifesci Capital Comments on JANX Q2 Earnings - MarketBeat
LifeSci Capital Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics (JANX) Eps Diluted (TTM) - Zacks Investment Research
Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $58 - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.41, Implies 178% Upside - TradingView
RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating - marketscreener.com
Wedbush Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $58 - Moomoo
Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.94, Implies 182% Upside - TradingView
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14 - TipRanks
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
Janux Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BMS partnership boosts cash for Janux Therapeutics (NASDAQ: JANX) despite loss - Stock Titan
Janux Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Milestone payment and strong cash fuel Janux (NASDAQ: JANX) pipeline - Stock Titan
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q1 Revenue $3.7M, vs. FactSet Est of $4.4M - marketscreener.com
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - Yahoo Finance
FMR LLC files 13G/A on JANX (NASDAQ: JANX) for 2.54M shares - Stock Titan
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):